Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$102.80
pos +1.10
+1.10%
Today's Range: 102.00 - 102.66 | JNJ Avg Daily Volume: 9,338,800
Last Update: 03/05/15 - 9:58 AM EST
Volume: 497,447
YTD Performance: -2.79%
Open: $102.00
Previous Close: $101.65
52 Week Range: $92.38 - $109.49
Oustanding Shares: 2,780,488,708
Market Cap: 284,555,214,377
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 5 5
Moderate Buy 3 3 3 3
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.06 2.13 2.13 2.13
Latest Dividend: 0.70
Latest Dividend Yield: 2.74%
Dividend Ex-Date: 02/20/15
Price Earnings Ratio: 17.95
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
17.95 18.00 27.80
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.49% 8.90% 56.94%
GROWTH 12 Mo 3 Yr CAGR
Revenue 4.20 0.14 0.05
Net Income 18.00 0.69 0.19
EPS 18.60 0.64 0.18
Earnings for JNJ:
EBITDA 24.85B
Revenue 74.33B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $1.53 $1.73 $6.21 $6.50
Number of Analysts 8 7 13 12
High Estimate $1.60 $1.86 $6.30 $6.61
Low Estimate $1.43 $1.50 $6.15 $6.32
Prior Year $1.54 $1.66 $5.97 $6.21
Growth Rate (Year over Year) -0.97% 4.22% 4.01% 4.68%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Mar 4, 2015 | 12:31 PM EST

Sector could regain its leadership role.

By

Jim Cramer

 | Mar 2, 2015 | 3:45 PM EST

It's almost comical how welcoming it is these days.

By

Jim Cramer

 | Feb 26, 2015 | 2:31 PM EST

But there's just too much good news.

By

Sham Gad

 | Feb 26, 2015 | 2:00 PM EST

It takes patience not to settle for a lesser idea.

By

Jim Cramer

 | Feb 23, 2015 | 11:59 AM EST

It is no pipedream that the stock could trade to $240.

By

David Katz

 | Feb 20, 2015 | 8:00 AM EST

JNJ provides low-risk, good income and modest appreciation.

By

Jim Cramer

 | Feb 2, 2015 | 12:05 PM EST

Even the best companies reporting can't sustain much lift.

By

Gary Berman

 | Jan 20, 2015 | 10:01 AM EST

I would look to buy the weakness inside the $102.30-$100.59 zone.

By

Chris Versace and Lenore Hawkins

 | Jan 18, 2015 | 5:00 PM EST

Watch the ECB, economic data, and earnings.

bearishJohnson & Johnson downgraded at Goldman

Jan 15, 2015 | 7:07 AM EST

JNJ was downgraded from Neutral to Sell, Goldman Sachs said. $97 price target. Company lacks near-term catalysts. 

I am now a seller (short) of all rallies. The complexion of the market might be changing. ...
Yesterday's bonce in shares of Alibaba (BABA) created a daily candle that has engulfed the...
It's been reported everywhere that Costco's (COST) latest quarter was boosted by a tax-ben...
Join me after the close for a great webinar session, talking volatility and markets. Free...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.